questionsmedicales.fr
Infection
Infections bactériennes et mycoses
Infections bactériennes
Infections bactériennes à Gram positif
Infections à Actinomycetales
Infections à Mycobacterium
Infections à mycobactéries non tuberculeuses
Lèpre
Lèpre : Questions médicales fréquentes
Termes MeSH sélectionnés :
Symptômes
5
Lèpre
Évolution des maladies
Traitements
5
Lèpre
Durée du traitement
Complications
5
Lèpre
Gestion des complications
Facteurs de risque
5
Lèpre
Statut socio-économique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lèpre : Questions médicales les plus fréquentes",
"headline": "Lèpre : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lèpre : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-09",
"dateModified": "2025-04-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lèpre"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Infections à mycobactéries non tuberculeuses",
"url": "https://questionsmedicales.fr/mesh/D009165",
"about": {
"@type": "MedicalCondition",
"name": "Infections à mycobactéries non tuberculeuses",
"code": {
"@type": "MedicalCode",
"code": "D009165",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.410.040.552.475"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Lèpre multibacillaire",
"alternateName": "Leprosy, Multibacillary",
"url": "https://questionsmedicales.fr/mesh/D056006",
"about": {
"@type": "MedicalCondition",
"name": "Lèpre multibacillaire",
"code": {
"@type": "MedicalCode",
"code": "D056006",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.410.040.552.475.371.775"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Lèpre lépromateuse",
"alternateName": "Leprosy, Lepromatous",
"url": "https://questionsmedicales.fr/mesh/D015440",
"about": {
"@type": "MedicalCondition",
"name": "Lèpre lépromateuse",
"code": {
"@type": "MedicalCode",
"code": "D015440",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.410.040.552.475.371.775.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Lèpre paucibacillaire",
"alternateName": "Leprosy, Paucibacillary",
"url": "https://questionsmedicales.fr/mesh/D056005",
"about": {
"@type": "MedicalCondition",
"name": "Lèpre paucibacillaire",
"code": {
"@type": "MedicalCode",
"code": "D056005",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.410.040.552.475.371.850"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Lèpre interpolaire",
"alternateName": "Leprosy, Borderline",
"url": "https://questionsmedicales.fr/mesh/D015439",
"about": {
"@type": "MedicalCondition",
"name": "Lèpre interpolaire",
"code": {
"@type": "MedicalCode",
"code": "D015439",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.410.040.552.475.371.850.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Lèpre tuberculoïde",
"alternateName": "Leprosy, Tuberculoid",
"url": "https://questionsmedicales.fr/mesh/D015441",
"about": {
"@type": "MedicalCondition",
"name": "Lèpre tuberculoïde",
"code": {
"@type": "MedicalCode",
"code": "D015441",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.252.410.040.552.475.371.850.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Lèpre",
"alternateName": "Leprosy",
"code": {
"@type": "MedicalCode",
"code": "D007918",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Euzenir Nunes Sarno",
"url": "https://questionsmedicales.fr/author/Euzenir%20Nunes%20Sarno",
"affiliation": {
"@type": "Organization",
"name": "Leprosy Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil."
}
},
{
"@type": "Person",
"name": "Wim H van Brakel",
"url": "https://questionsmedicales.fr/author/Wim%20H%20van%20Brakel",
"affiliation": {
"@type": "Organization",
"name": "NLR, Amsterdam, Netherlands."
}
},
{
"@type": "Person",
"name": "Tarun Narang",
"url": "https://questionsmedicales.fr/author/Tarun%20Narang",
"affiliation": {
"@type": "Organization",
"name": "Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India."
}
},
{
"@type": "Person",
"name": "Sunil Dogra",
"url": "https://questionsmedicales.fr/author/Sunil%20Dogra",
"affiliation": {
"@type": "Organization",
"name": "Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India."
}
},
{
"@type": "Person",
"name": "Mariana Andrea Hacker",
"url": "https://questionsmedicales.fr/author/Mariana%20Andrea%20Hacker",
"affiliation": {
"@type": "Organization",
"name": "Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil. marianah@ioc.fiocruz.br."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Tranexamic acid for percutaneous nephrolithotomy.",
"datePublished": "2023-10-26",
"url": "https://questionsmedicales.fr/article/37882229",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD015122.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tranexamic acid: Beyond antifibrinolysis.",
"datePublished": "2022-07-14",
"url": "https://questionsmedicales.fr/article/35834488",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/trf.16976"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prehospital Tranexamic Acid for Severe Trauma.",
"datePublished": "2023-06-14",
"url": "https://questionsmedicales.fr/article/37314244",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1056/NEJMoa2215457"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tranexamic acid in pediatric hemorrhagic trauma.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36044459",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/TA.0000000000003775"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oral tranexamic acid with a triple combination cream versus oral tranexamic acid monotherapy in the treatment of severe melasma.",
"datePublished": "2022-06-07",
"url": "https://questionsmedicales.fr/article/35340120",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jocd.14942"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Infection",
"item": "https://questionsmedicales.fr/mesh/D007239"
},
{
"@type": "ListItem",
"position": 3,
"name": "Infections bactériennes et mycoses",
"item": "https://questionsmedicales.fr/mesh/D001423"
},
{
"@type": "ListItem",
"position": 4,
"name": "Infections bactériennes",
"item": "https://questionsmedicales.fr/mesh/D001424"
},
{
"@type": "ListItem",
"position": 5,
"name": "Infections bactériennes à Gram positif",
"item": "https://questionsmedicales.fr/mesh/D016908"
},
{
"@type": "ListItem",
"position": 6,
"name": "Infections à Actinomycetales",
"item": "https://questionsmedicales.fr/mesh/D000193"
},
{
"@type": "ListItem",
"position": 7,
"name": "Infections à Mycobacterium",
"item": "https://questionsmedicales.fr/mesh/D009164"
},
{
"@type": "ListItem",
"position": 8,
"name": "Infections à mycobactéries non tuberculeuses",
"item": "https://questionsmedicales.fr/mesh/D009165"
},
{
"@type": "ListItem",
"position": 9,
"name": "Lèpre",
"item": "https://questionsmedicales.fr/mesh/D007918"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lèpre - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lèpre",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lèpre",
"description": "Comment diagnostique-t-on la lèpre ?\nQuels tests sont utilisés pour la lèpre ?\nLa lèpre est-elle contagieuse ?\nQuels signes cliniques indiquent la lèpre ?\nPeut-on détecter la lèpre par des analyses sanguines ?",
"url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Tranexamic+Acid#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lèpre",
"description": "Quels sont les symptômes de la lèpre ?\nLa lèpre cause-t-elle des douleurs ?\nLes lésions de la lèpre sont-elles douloureuses ?\nComment évoluent les symptômes de la lèpre ?\nPeut-on avoir des symptômes sans être contagieux ?",
"url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Tranexamic+Acid#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lèpre",
"description": "Comment prévenir la lèpre ?\nLes vaccins protègent-ils contre la lèpre ?\nFaut-il éviter les personnes atteintes de lèpre ?\nQuelles mesures de santé publique sont prises ?\nLa lèpre est-elle une maladie évitable ?",
"url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Tranexamic+Acid#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lèpre",
"description": "Quel est le traitement de la lèpre ?\nLa lèpre peut-elle être guérie ?\nCombien de temps dure le traitement de la lèpre ?\nY a-t-il des effets secondaires au traitement ?\nLe traitement de la lèpre est-il gratuit ?",
"url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Tranexamic+Acid#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lèpre",
"description": "Quelles sont les complications de la lèpre ?\nLa lèpre peut-elle entraîner des handicaps ?\nLes complications sont-elles réversibles ?\nComment gérer les complications de la lèpre ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Tranexamic+Acid#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lèpre",
"description": "Qui est à risque de développer la lèpre ?\nL'immunité joue-t-elle un rôle dans la lèpre ?\nLes enfants sont-ils plus à risque ?\nLe statut socio-économique influence-t-il le risque ?\nLes personnes immunodéprimées sont-elles plus vulnérables ?",
"url": "https://questionsmedicales.fr/mesh/D007918?mesh_terms=Tranexamic+Acid#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la lèpre ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et des tests cutanés pour détecter les bacilles."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la lèpre ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de sensibilité cutanée et des biopsies peuvent être réalisés pour confirmer la lèpre."
}
},
{
"@type": "Question",
"name": "La lèpre est-elle contagieuse ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "La lèpre n'est pas très contagieuse; elle se propage par contact prolongé avec une personne infectée."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent la lèpre ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des lésions cutanées, des engourdissements et des déformations peuvent indiquer la lèpre."
}
},
{
"@type": "Question",
"name": "Peut-on détecter la lèpre par des analyses sanguines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les analyses sanguines ne sont pas spécifiques; le diagnostic repose principalement sur l'examen clinique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la lèpre ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des lésions cutanées, des engourdissements et des douleurs nerveuses."
}
},
{
"@type": "Question",
"name": "La lèpre cause-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la lèpre peut provoquer des douleurs nerveuses et des sensations anormales."
}
},
{
"@type": "Question",
"name": "Les lésions de la lèpre sont-elles douloureuses ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les lésions cutanées sont souvent indolores, mais peuvent s'infecter et causer des douleurs."
}
},
{
"@type": "Question",
"name": "Comment évoluent les symptômes de la lèpre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent évoluer lentement, avec des périodes d'aggravation et d'amélioration."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans être contagieux ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une personne peut avoir des symptômes sans être contagieuse, surtout en début d'infection."
}
},
{
"@type": "Question",
"name": "Comment prévenir la lèpre ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention repose sur le dépistage précoce et le traitement des personnes infectées."
}
},
{
"@type": "Question",
"name": "Les vaccins protègent-ils contre la lèpre ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de vaccin spécifique contre la lèpre, mais des recherches sont en cours."
}
},
{
"@type": "Question",
"name": "Faut-il éviter les personnes atteintes de lèpre ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, avec un traitement, les personnes atteintes ne sont plus contagieuses et peuvent être approchées."
}
},
{
"@type": "Question",
"name": "Quelles mesures de santé publique sont prises ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes de sensibilisation et de dépistage sont mises en place pour contrôler la lèpre."
}
},
{
"@type": "Question",
"name": "La lèpre est-elle une maladie évitable ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la lèpre est évitable grâce à un diagnostic précoce et un traitement adéquat."
}
},
{
"@type": "Question",
"name": "Quel est le traitement de la lèpre ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement standard est une polychimiothérapie (PCT) avec des antibiotiques comme la rifampicine."
}
},
{
"@type": "Question",
"name": "La lèpre peut-elle être guérie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la lèpre est curable avec un traitement approprié et précoce."
}
},
{
"@type": "Question",
"name": "Combien de temps dure le traitement de la lèpre ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dure généralement de 6 mois à 2 ans, selon la forme de la maladie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires au traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent survenir, mais ils sont généralement légers et gérables."
}
},
{
"@type": "Question",
"name": "Le traitement de la lèpre est-il gratuit ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans de nombreux pays, le traitement de la lèpre est gratuit et accessible."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de la lèpre ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions nerveuses, des déformations et des infections secondaires."
}
},
{
"@type": "Question",
"name": "La lèpre peut-elle entraîner des handicaps ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des lésions nerveuses peuvent causer des handicaps permanents si non traitées."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement précoce, d'autres non."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications de la lèpre ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite un suivi médical et des soins adaptés aux lésions."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Qui est à risque de développer la lèpre ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes vivant dans des zones endémiques et celles en contact avec des malades sont à risque."
}
},
{
"@type": "Question",
"name": "L'immunité joue-t-elle un rôle dans la lèpre ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une immunité affaiblie augmente le risque de développer la lèpre."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants peuvent être à risque, mais la maladie touche principalement les adultes."
}
},
{
"@type": "Question",
"name": "Le statut socio-économique influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un faible statut socio-économique est associé à un risque accru de lèpre."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles plus vulnérables ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées ont un risque accru de contracter la lèpre."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 04/04/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
Leprosy Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil.
Publications dans "Lèpre" :
4 publications dans cette catégorie
Affiliations :
NLR, Amsterdam, Netherlands.
Publications dans "Lèpre" :
3 publications dans cette catégorie
Affiliations :
Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Publications dans "Lèpre" :
3 publications dans cette catégorie
Affiliations :
Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Publications dans "Lèpre" :
3 publications dans cette catégorie
Affiliations :
Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil. marianah@ioc.fiocruz.br.
Publications dans "Lèpre" :
3 publications dans cette catégorie
Affiliations :
Department of Dermatology and Venereology, Faculty of Medicine, Padjadjaran University, Dr Hasan Sadikin Hospital, Bandung, Indonesia.
Publications dans "Lèpre" :
3 publications dans cette catégorie
Affiliations :
Department of Dermatology and Venereology, Faculty of Medicine, Padjadjaran University, Dr Hasan Sadikin Hospital, Bandung, Indonesia.
Publications dans "Lèpre" :
3 publications dans cette catégorie
Affiliations :
Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Publications dans "Lèpre" :
3 publications dans cette catégorie
Affiliations :
Institute for Specialized Services in Leprosy (INSSIL), Nireekshana ACET, Hyderabad, Telangana, India.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Leprosy Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Leprosy Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Leprosy Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, RJ, 21040-360, Brazil.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology and Venereology, Faculty of Medicine, Padjadjaran University, Dr Hasan Sadikin Hospital, Bandung, Indonesia.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Instituto Colombiano de Medicina Tropical-Universidad CES, Medellín, Colombia.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Instituto Colombiano de Medicina Tropical-Universidad CES, Medellín, Colombia.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Haramaya University, College of Health and Medical Sciences, Harar, Ethiopia.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Publications dans "Lèpre" :
2 publications dans cette catégorie
Affiliations :
College of Health and Medical Sciences, Department of Nursing, Meda Walebu University, Shashamane, Ethiopia.
Publications dans "Lèpre" :
Percutaneous nephrolithotomy (PCNL) is the gold standard for the treatment of large kidney stones but comes with an increased risk of bleeding compared to other treatments, such as ureteroscopy and sh...
To assess the effects of TXA in individuals with kidney stones undergoing PCNL....
We performed a comprehensive literature search of the Cochrane Library, PubMed (including MEDLINE), Embase, Scopus, Global Index Medicus, trials registries, other sources of the grey literature, and c...
We included randomized controlled trials (RCTs) that compared treatment with PCNL with administration of TXA to placebo (or no TXA) for patients ≥ 18 years old....
Two review authors independently classified studies and abstracted data. Primary outcomes were: blood transfusion, stone-free rate (SFR), and thromboembolic events (TEEs). Secondary outcomes were: adv...
We analyzed 10 RCTs assessing the effect of systemic TXA in PCNL versus placebo (or no TXA) with 1883 randomized participants. Eight studies were published as full text. One was published in abstract ...
Based on 10 RCTs with substantial methodological limitations that lowered all CoE of effect, we found that systemic TXA in PCNL may reduce blood transfusions, major and minor surgical complications, a...
Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthopedic, and gynecological surgical patients. TXA binds plasminogen and preve...
Whether prehospital administration of tranexamic acid increases the likelihood of survival with a favorable functional outcome among patients with major trauma and suspected trauma-induced coagulopath...
We randomly assigned adults with major trauma who were at risk for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus dose of 1 g before hospital admission, ...
A total of 1310 patients were recruited by 15 emergency medical services in Australia, New Zealand, and Germany. Of these patients, 661 were assigned to receive tranexamic acid, and 646 were assigned ...
Among adults with major trauma and suspected trauma-induced coagulopathy who were being treated in advanced trauma systems, prehospital administration of tranexamic acid followed by an infusion over 8...
There is strong evidence in adult literature that tranexamic acid (TXA) given within 3 hours from injury is associated with improved outcomes. The evidence for TXA use in injured children is limited t...
Melasma is an acquired pigmentation disorder with a complex multifactorial etiopathogenesis. Oral tranexamic acid (TA) is a promising drug for its treatment and may enhance outcomes when used in combi...
To provide evidence of the efficacy and safety of oral TA as a monotherapy, and in combination with a triple combination cream, for treating melasma in the Hispanic population....
Forty-four female Hispanic patients with melasma were randomly assigned to receive 325 mg of oral TA every 12 h plus f-TCC (fluocinolone-based triple combination cream) every 24 h (group A) or 325 mg ...
There was a 50.04% and 65.45% improvement in mMASI at Weeks 4 and 8, respectively, in group A, compared to baseline, while for Week 16, an improvement of 76.85% was achieved in group B compared to bas...
The combination of oral TA and f-TCC is more effective than oral TA alone in the treatment of severe melasma in Hispanic patients....
In the last decades, tranexamic acid (TXA) has emerged as an essential tool in blood loss management in obstetrics. TXA prophylaxis for postpartum haemorrhage (PPH) has been studied in double-blind, p...
Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood loss and allogeneic red blood cell transfusion in several clinical settings. With a growing emphasis on pa...
Tranexamic acid (TXA) is a common haemorrhage control agent in both emergency department (ED) settings and intra-operatively. While efficacy and potential harms are well-studied, there are no overview...
Tranexamic acid reduces surgical bleeding. Consistent with previous research, the POISE-3 (Peri-Operative Ischemic Evaluation-3) trial found that tranexamic acid reduces major bleeding by 25% and with...
Melasma is a hyperpigmentary disorder causing cosmetic disfigurement. We aimed to compare the efficacy and safety of tranexamic acid (TXA) microinjections with TXA mesoneedling for facial melasma....
This randomized assessor-blind split-face controlled trial included patients with symmetric facial melasma. One side of the face received TXA (100 mg/ml) mesoneedling and the other side intradermal TX...
All 27 patients included in the study were female (mean age: 44.22 ± 8.39 years). Both groups were comparable in terms of mMASI scores before and after treatment (standardized mean difference [SMD] = ...
TXA mesoneedling was comparable with TXA microinjection in the treatment of facial melasma, while patient satisfaction was significantly higher with TXA mesoneedling; however, the high frequency of co...